Cargando…

Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?

SIMPLE SUMMARY: In oncology, a new era has emerged in the last ten years with the development of targeted and immune therapies. In hepatocellular carcinoma (HCC), several targeted agents (sorafenib, lenvatinib, cabozantinib, regorafenib, and ramucirumab) are approved and immunotherapy is now validat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boilève, Alice, Hilmi, Marc, Delaye, Matthieu, Tijeras-Raballand, Annemilaï, Neuzillet, Cindy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198554/ https://www.ncbi.nlm.nih.gov/pubmed/34070929 http://dx.doi.org/10.3390/cancers13112708

Ejemplares similares

Targeting cancer cell metabolism in pancreatic adenocarcinoma
por: Cohen, Romain, et al.
Publicado: (2015)

Pancreatic cancer orthotopic graft in a murine model
por: Muzzolini, Milena, et al.
Publicado: (2023)

Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas
por: Neuzillet, Cindy, et al.
Publicado: (2013)

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients
por: Serova, Maria, et al.
Publicado: (2015)

Periostin‐ and podoplanin‐positive cancer‐associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma
por: Neuzillet, Cindy, et al.
Publicado: (2022)

Professional and Psychological Impacts of the COVID-19 Pandemic on Oncology Residents: A National Survey
por: Hilmi, Marc, et al.
Publicado: (2020)

Inter‐ and intra‐tumoural heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal adenocarcinoma
por: Neuzillet, Cindy, et al.
Publicado: (2019)

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)

Rosuvastatin Counteracts Vessel Arterialisation and Sinusoid Capillarisation, Reduces Tumour Growth, and Prolongs Survival in Murine Hepatocellular Carcinoma
por: Tijeras-Raballand, Annemilaï, et al.
Publicado: (2010)

Immune Therapy for Liver Cancers
por: Hilmi, Marc, et al.
Publicado: (2019)

Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion
por: Hilmi, Marc, et al.
Publicado: (2020)

Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
por: Hilmi, Marc, et al.
Publicado: (2018)

Immunotherapy in Advanced Biliary Tract Cancers
por: Boilève, Alice, et al.
Publicado: (2021)

Inclusion of patients with chronic kidney disease in randomized phase 3 clinical trials in patients with prostate, breast, lung, and colorectal cancer
por: Delaye, Matthieu, et al.
Publicado: (2022)

Use of Serum MicroRNAs as Biomarker for Hepatobiliary Diseases in Dogs
por: Dirksen, K., et al.
Publicado: (2016)

Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions
por: Hilmi, Marc, et al.
Publicado: (2019)

Hepatobiliary
Publicado: (2013)

Practice patterns of hepatobiliary surgery within the military
por: Suydam, Camille R., et al.
Publicado: (2023)

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma
por: Santos, C D, et al.
Publicado: (2015)

Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study
por: Evrard, Diane, et al.
Publicado: (2022)

Hereditary Pancreatic and Hepatobiliary Cancers
por: Haddad, Ashraf, et al.
Publicado: (2011)

The State of Immunotherapy in Hepatobiliary Cancers
por: Ilyas, Farhan Z., et al.
Publicado: (2021)

Hepatobiliary tuberculosis
por: Chaudhary, Poras
Publicado: (2014)

Hepatobiliary Cystadenocarcinoma
por: Wilkinson, Neal
Publicado: (2012)

Hepatobiliary Schistosomiasis
por: Shaker, Yehia, et al.
Publicado: (2014)

Hepatobiliary Disease
por: DAILY, JOHANNA P., et al.
Publicado: (2006)

Hepatobiliary Brucellosis: Brucella Bacteremia Presenting with Refractory Hepatobiliary Infection
por: El Hallak, Dania, et al.
Publicado: (2023)

Hepatobiliary phases in magnetic resonance imaging using liver-specific contrast for focal lesions in clinical practice
por: Fernandes, Daniel Alvarenga, et al.
Publicado: (2022)

MicroRNAs in Hepatobiliary and Pancreatic Cancers
por: Saito, Yoshimasa, et al.
Publicado: (2011)

The Diagnostic Roles of Cytokines in Hepatobiliary Cancers
por: Koca, Yavuz Savas, et al.
Publicado: (2017)

Molecular genomic landscapes of hepatobiliary cancer
por: Shibata, Tatsuhiro, et al.
Publicado: (2018)

Advances in Targeted Immunotherapy for Hepatobiliary Cancers
por: Ruff, Samantha M., et al.
Publicado: (2022)

Advances in the Early Detection of Hepatobiliary Cancers
por: Yıldırım, Hasan Çağrı, et al.
Publicado: (2023)

Hepatobiliary manifestations in inflammatory bowel disease: A practical approach
por: Núñez F, Paulina, et al.
Publicado: (2022)

Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition
por: Ulloa, Jose L, et al.
Publicado: (2013)

An Update to Hepatobiliary Stents
por: Moy, Brian T., et al.
Publicado: (2015)

MRI with hepatobiliary contrast
por: Jhaveri, Kartik S
Publicado: (2015)

Hepatobiliary and pancreatic ascariasis
por: Khuroo, Mohammad S, et al.
Publicado: (2016)

Update on Hepatobiliary Plasticity
por: Kim, Minwook, et al.
Publicado: (2023)

Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors
por: Hammel, Pascal, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pr1bfmh2nj7vsv9ghmogeq47kr